Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.
Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculous therapy. Physicians should be aware of the increased risk of a paradoxical response in this population and should consider the use of corticosteroids when a paradoxical reaction is suspected.
Garcia Vidal
Carolina
C
Service of Internal Medicine, Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain.
Rodríguez Fernández
Serena
S
Martínez Lacasa
Javier
J
Salavert
Miquel
M
Vidal
Rafael
R
Rodríguez Carballeira
Monica
M
Garau
Javier
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab